Features of various options for anticoagulant therapy for a new coronavirus infection against the background of obesity

Background. When treating a new coronavirus infection, the prevention of venous thromboembolic complications in obese patients is of particular importance. Aim. To analyze various options for anticoagulant therapy in obese and non-obese patients in the treatment of a new coronavirus infection. Material and methods. The patients were divided into two groups: the first group obese patients 151 (40.8%) people [average age 63 (5669) years], the second group without obesity 219 (59.2%) people [average age 63 (51.571.0) years], p=0.998. According to the prescribed anticoagulant and the presence of obesity, patients were divided into subgroups: subgroup 1 non-obese + low-molecular-weight heparin (n=114), subgroup 2 non-obese + unfractionated heparin (n=58), subgroup 3 obesity + low-molecular-weight heparin (n=76), subgroup 4 obesity + unfractionated heparin (n=66). Venous thrombotic complications and bleeding rates were assessed. Analysis of qualitative indicators was performed using Pearson 2 and Fisher tests. The distribution of quantitative indicators was assessed using the KolmogorovSmirnov and ShapiroWilk tests (p 0.05). Due to the non-normal distribution of indicators, mean values were presented as median (Me) and interquartile range (Q1Q3), and analysis was carried out using Wilcoxon, MannWhitney and KruskalWallis tests. Results. In nonobese patients, a comparable incidence of deep vein thrombosis was noted on low molecular weight heparin and unfractionated heparin 1 (0.9%) case versus 3 (5.2%) cases (p=0.102). At the same time, there was a statistically significant difference in the frequency of pulmonary embolism without a source according to autopsy data 2 (1.8%) versus 4 (6.9%) cases (p=0.004). In obese patients receiving unfractionated heparin, the incidence of this complication was higher and amounted to 9 (13.6%), and in patients receiving low molecular weight heparin 2 (2.6%) cases (p=0.004). A higher incidence of bleeding was observed in patients with obesity compared to patients without it (10.6 vs 4.7% of cases, p=0.045). When analyzing hemorrhagic complications, it was found that the incidence of major and significant bleeding was higher in patients receiving unfractionated heparin rather than low molecular weight heparin (16.7 vs 5.3% of cases, p 0.001). Conclusion. The use of low molecular weight heparin in obese patients with new coronavirus infection was associated with a low incidence of pulmonary embolism and bleeding compared with patients receiving unfractionated heparin.